- Home
- Equipment
- usa california
- natural killer chimeric antigen receptor cells
Refine by
Natural Killer Chimeric Antigen Receptor Cells Equipment Supplied In Usa California
22 equipment items found
Manufactured by:DIAGNOSTIC BIOSYSTEMS INC. based inPleasanton, CALIFORNIA (USA)
CD7 is expressed by most peripheral blood T cells, NK cells, and all thymocytes. It is one of the earliest surface antigens on T and NK-cell lineages. The antibody is a useful aid for classification of T-cell malignancies ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
Pursuing an Unmet Need in the Treatment of CRC - SENTI-401 is designed to more precisely target and eliminate colorectal cancer (CRC) cells while sparing healthy cells elsewhere in the body. Our vision is a potential medicine that more effectively treats patients with colorectal ...
Manufactured by:Nkarta, Inc. based inSouth San Francisco, CALIFORNIA (USA)
OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for enhanced anti-tumor activity. ...
by:Caribou Biosciences, Inc. based inBerkeley, CALIFORNIA (USA)
Natural killer (NK) cells, as their name implies, play an important role in ridding the body of cancer and viruses. NK cells are emerging as an increasingly important cell type for therapeutic development. Solid tumors are particularly challenging to treat and CAR-T cells have largely underperformed in the solid tumor setting. NK cells, however, inherently target both primary solid tumors and ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
Pursuing an Unmet Need in the Treatment of AML - SENTI-202 is designed to target and eliminate acute myeloid leukemia cells while sparing healthy bone marrow. Our vision is a potential medicine that does not rely on an invasive bone marrow ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
B7H3 belongs to the B7 family of immune checkpoint inhibitors and is expressed on a wide range of solid and hematologic malignancies. B7H3 is an important mediator of tumor angiogenesis and metastasis, and higher expression is associated with a poor prognosis for patients. We are developing FT573, an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
In addition to CD38 targeting in multiple myeloma, targeting of other tumor-associated cell-surface proteins has been clinically investigated. Of these antigens, the TNF-superfamily member B-cell Maturation Antigen (BCMA) is among the most researched. Several clinical trials in multiple myeloma have shown promising initial results targeting BCMA with CAR T cells. ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
MICA and MICB (MICA/B) are stress proteins expressed on a broad range of solid and hematopoietic tumor cells and serve as an activation signal for NKG2D+ NK and T cells. However, MICA/B are frequently shed as an immune escape mechanism, preventing recognition and destruction of tumor cells by the immune system. Proteolytic shedding of MICA/B can be inhibited by monoclonal antibodies targeting the ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
Natural Killer (NK) cells are essential components of the immune system, playing an important role in the body’s defensive response against tumors and infected cells. NK cells constantly patrol the body to detect and neutralize foreign cells. Senti Bio believes there are several advantages that NK cells confer in relation to other potential immune cell types in oncology: innate killing, ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Probody therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment to more effectively localize treatment to the tumor, while limiting activity in healthy tissues. These novel therapies are designed to take advantage of high levels of protease activity in the tumor microenvironment. Their target-binding regions are masked to limit activity ...
Manufactured by:AllCells based inAlameda, CALIFORNIA (USA)
AllCells’ GMP Fresh Leukopak products are collected by apheresis from peripheral blood of healthy donors. Our Leukopaks contain a high concentration of lymphocyte populations, T Cells, B Cells, NK Cells, and monocytes. AllCells maintains on-site, FDA-registered donor centers for the collection of all products from IRB-consented healthy donors providing customers with a streamlined process ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Multiple myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow and produce abnormal antibodies called M proteins, which can cause kidney damage, bone destruction, and impaired immune function. While multiple approved drugs with novel mechanisms have improved disease management ...
Manufactured by:Nkarta, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Cell therapy, a new approach that uses immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. First generation approaches have focused on T-cells, which have shown great promise in hematologic malignancies but are plagued with unwanted side effects and, to date, have not shown similar activity in solid tumors. Nkarta was founded to address these ...
Manufactured by:AllCells based inAlameda, CALIFORNIA (USA)
Leukopaks are enriched leukapheresis products collected from healthy and consenting donors using the Spectra Optia® Apheresis System following an IRB-approved protocol. Leukopaks typically contain up to 50% T cells, 20% monocytes, 10% B cells, 10% NK cells, 3% granulocytes, and 3% hematocrit. Leukapheresis results in high yields of single-donor mononuclear cells (MNCs) compared to ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
NK cells play a major role in the anti-tumor efficacy of certain tumor-antigen targeting antibodies. NK cells express CD16, an activating receptor that binds to the Fc portion of IgG antibodies. Once activated through CD16, NK cells are able to destroy antibody-coated target cells and secrete cytokines, such as interferon gamma, to recruit and potentiate adaptive immune cells, including T cells. ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
The oncology therapeutic landscape has been transformed with the use of checkpoint inhibitor therapy. Despite the clinical benefit conferred by approved checkpoint inhibitor therapy against a variety of tumor types, these therapies are not curative and, in most cases, patients either fail to respond or their disease progresses on these agents. Resistance to checkpoint inhibitor therapy has been ...
Manufactured by:Ibio, Inc. based inBryan, TEXAS (USA)
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid tumors, significant challenges remain. This is in part due to dynamics in the tumor microenvironment, wherein regulatory T cells [Tregs] proliferate and suppress the ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers and clinical investigators continue to focus on the development of autologous or allogeneic CAR T-cell therapies, we are developing CAR NK cell product candidates created from clonal master engineered ...
Manufactured by:Adicet Bio based inMenlo Park, CALIFORNIA (USA)
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet to be proven. The cell platform and novel targeting approaches Adicet is developing are aimed at harnessing the tumor specific immunity of gamma delta ...